CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Operating activities:
Net loss	$ (1,426)	$ (85)
Adjustments to reconcile net loss to net cash provided by operating activities, net of acquisition:
Depreciation and amortization	732	713
Amortization finance lease	32
Employee stock compensation expense	81	25
Gain on disposal of property and equipment		(3)
Unrealized foreign currency gains	18	(146)
Changes in operating assets and liabilities:
Accounts receivable	(1,013)	516
Inventories	61	10
Income tax accruals	97
Prepaid expenses and other assets	(774)	(227)
Accounts payable	479	(532)
Accrued expenses	666	317
Customer advances	2,501	319
Net cash provided by operating activities	1,454	907
Investing activities:
Capital expenditures	(4,000)
Cash paid in acquisition	(2,165)	(684)
Net cash used by investing activities	(6,165)	(684)
Financing activities:
Payments on finance lease liability	(37)
Payments of long-term debt	(250)	(224)
Payments of debt issuance costs	(110)	(11)
Payments on revolving line of credit	(10,531)	(5,892)
Borrowings on revolving line of credit	10,194	5,892
Borrowing on construction loan	1,183
Borrowing on capex line of credit	728
Payments on capital lease obligations		(38)
Borrowing on long-term loan	3,439
Net cash provided by (used in) financing activities	4,616	(273)
Net decrease in cash and cash equivalents	(95)	(50)
Cash and cash equivalents at beginning of period	606	773
Cash and cash equivalents at end of period	511	723
Supplemental disclosure of cash flow information:
Cash paid for interest	270	$ 116
Preclinical Research Services acquisition:
Assets acquired	6,435
Liabilities assumed	(1,302)
Common shares issued	(1,133)
Cash paid	4,000
Smithers Avanza Toxicology Services LLC acquisition
Operating activities:
Net loss	$ 31